Tenatumomab

• CAT Number: I042121
• CAS Number: 1412891-40-7
• Purity: ≥95%

Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach[1][2].
Tenascin-C is a hexameric glycoprotein found in the extracellular matrix of embryos and adults. It has preferential expression in malignant solid tumors and hematologic tumors. Tenascin-C is spatially and temporally associated with tumor neovasculars and may exert anti-adhesion and immunosuppressive activities[2].
Tenatumomab (2-5 μg/mL; 16 h) retains immunoreactivity upon biotinylation. And Tenatumomab can be conjugated to up to 20 biotins per mAb,maintaining >50% immunoreactivity[2].
Tenatumomab (4 μg/mouse; i.v.; single dose) shows a biodistribution associated with low and high tenascin expression in nude mice transplanted with human HT-29 colon carcinoma and/or human U-118MG glioblastoma cells, respectively[2].

Reference

[1]. Giannini G, et al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253.
 [Content Brief]

[2]. De Santis R, et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2191-6.
 [Content Brief]